Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ARWR
- Price
- 11.24
- Stock movement down
- -0.11 (-0.97%)
- Company name
- Arrowhead Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.40B
- Ent value
- 2.24B
- Price/Sales
- 393.87
- Price/Book
- 7.32
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -52.51%
- 3 year return
- -37.86%
- 5 year return
- -21.10%
- 10 year return
- 3.46%
Last updated: 2025-04-18
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ARWR does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 393.87 |
| Price to Book | 7.32 |
| EV to Sales | 632.13 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 124.43M |
| EPS (TTM) | -4.82 |
| FCF per share (TTM) | -4.85 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 3.55M |
| Gross profit (TTM) | -10.02M |
| Operating income (TTM) | -601.08M |
| Net income (TTM) | -599.49M |
| EPS (TTM) | -4.82 |
| EPS (1y forward) | -4.37 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -282.15% |
| Operating margin (TTM) | -16927.06% |
| Profit margin (TTM) | -16882.37% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 102.69M |
| Net receivables | 0.00 |
| Total current assets | 695.47M |
| Goodwill | 0.00 |
| Intangible assets | 8.56M |
| Property, plant and equipment | 489.31M |
| Total assets | 1.14B |
| Accounts payable | 11.39M |
| Short/Current long term debt | 510.55M |
| Total current liabilities | 103.17M |
| Total liabilities | 948.74M |
| Shareholder's equity | 191.06M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -462.85M |
| Capital expenditures (TTM) | 141.47M |
| Free cash flow (TTM) | -604.32M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -313.77% |
| Return on Assets | -52.60% |
| Return on Invested Capital | -101.51% |
| Cash Return on Invested Capital | -102.33% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 11.27 |
| Daily high | 11.51 |
| Daily low | 10.92 |
| Daily Volume | 2.38M |
| All-time high | 2762.50 |
| 1y analyst estimate | 47.43 |
| Beta | 0.93 |
| EPS (TTM) | -4.82 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 7 May 2025 |
Downside potential
Loading...
Downside potential data
| ARWR | S&P500 | |
| Current price drop from All-time high | -99.59% | -14.12% |
| Highest price drop | -99.96% | -56.47% |
| Date of highest drop | 20 Dec 2016 | 9 Mar 2009 |
| Avg drop from high | -98.39% | -11.07% |
| Avg time to new high | 5918 days | 12 days |
| Max time to new high | 5917 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.40B
Marketcap category
Small-cap
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
Employees
525
Website
Investor relations
-
SEC filings
CEO
Christopher Richard Anzalone
Country
USA
City
Pasadena
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page